论文部分内容阅读
目的:明确肺癌组织hMLH1及hMSH2表达对晚期非小细胞肺癌(non-samll cell lung cancer,NSCLC)含铂化疗疗效及生存的预测价值。方法:采用免疫组织化学的方法对39例福尔马林固定石蜡包埋NSCLC标本进行hMLH1、hMSH2检测,并分析二者与化疗疗效及生存之间的关系。结果:61.5%(24/39)有hMLH1的表达,66.7%(26/39)有hMSH2表达。hMLH1和hMSH2的表达与患者的性别、年龄、肿瘤病理类型、肿瘤分化程度、吸烟史及吸烟指数均无相关性;二者的表达对化疗的反应率(Response Rate,RR)和总生存(Overall Survival,OS)也无预测作用;hMLH1阳性者的至疾病进展时间(Time To Progression,TTP)较hMLH1阴性者明显延长,二者分别为10.9和6.1个月(P<0.05)。hMSH2表达与否对TTP没有影响。结论:hMSH1在肺癌组织的表达情况可能预测晚期NSCLC患者一线化疗的TTP。
Objective: To investigate the predictive value of hMLH1 and hMSH2 expression in patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-containing chemotherapy. Methods: Immunohistochemistry was used to detect hMLH1 and hMSH2 in 39 cases of formalin-fixed paraffin-embedded NSCLC specimens. The relationship between them and the efficacy and survival of chemotherapy was analyzed. Results: 61.5% (24/39) had hMLH1 expression and 66.7% (26/39) had hMSH2 expression. The expression of hMLH1 and hMSH2 had no correlation with the patient’s gender, age, tumor pathological type, tumor differentiation, smoking history and smoking index. The expressions of both response rate (RR) and overall survival Survival, OS) also had no predictive effect. Time to Progression (TTP) of hMLH1-positive patients was significantly longer than that of hMLH1-negative patients, both of which were 10.9 and 6.1 months respectively (P <0.05). hMSH2 expression has no effect on TTP. Conclusion: The expression of hMSH1 in lung cancer may predict the TTP of first-line chemotherapy in patients with advanced NSCLC.